Program
FXR0906
A development code. Also written as “FXR0906 injection”, “Intervention1: FXR0906 injection” and “Intervention2: FXR0906 injection”.
In Fosun Pharma's pipeline, ApoC3 siRNA
. Its studies are led by Fosun Pharma.
Furthest: phase 2, since Oct 13, 20262 company-led studies, 2 open or runningNext primary completion: Sep 24, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharma | 22 open or running | phase 2since Oct 13, 2026 | Jul 27, 2026 | Sep 24, 2027phase 1 · NCT07766759 |
- Named in Fosun Pharma’s own pipeline as
FXR0906 (ApoC3 siRNA)
, phase 2, as of Sep 21, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 27, 2026First study: phase 1 study in Healthy Adult VolunteersFirst studyNCT07766759 · 24 planned · China
- Oct 13, 2026Phase 2 study in DiseasePhase 2 reachedNCT07889245 · 192 planned · China
Ahead
- Sep 24, 2027Primary completion: phase 1 study in Healthy Adult VolunteersNCT07766759
- Aug 24, 2028Primary completion: phase 2 study in DiseaseNCT07889245
TargetBeta
“ApoC3 siRNA”the company's pipeline, read by Claude · source
Other programs on APOC3
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07889245Disease · China | 2 | Not yet recruiting | Aug 24, 2028 | 192 |
| NCT07766759Healthy Adult Volunteers · China | 1 | Not yet recruiting | Sep 24, 2027 | 24 |
How it is read
Names in the registry
- “FXR0906 injection”, 3 entries
- “Intervention1: FXR0906 injection”, 1 entry
- “Intervention2: FXR0906 injection”, 1 entry
Codes read as this program: FXR0906.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.